Edition:
United Kingdom

Transgene SA (TRNG.PA)

TRNG.PA on Paris Stock Exchange

3.04EUR
17 Jan 2018
Change (% chg)

€-0.00 (-0.16%)
Prev Close
€3.05
Open
€3.10
Day's High
€3.15
Day's Low
€3.02
Volume
125,538
Avg. Vol
141,960
52-wk High
€3.79
52-wk Low
€2.40

Chart for

About

Transgene SA is a biopharmaceutical company. The Company designs and develops immunotherapy products to treat cancer and infectious diseases. These products use viral vectors to directly or indirectly destroy diseased cells. The Company has approximately three products in clinical development: two immunotherapy products for... (more)

Overall

Beta: -0.15
Market Cap(Mil.): €186.79
Shares Outstanding(Mil.): 56.43
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 84.57 16.44
EPS (TTM): -- -- --
ROI: -- 3.42 10.61
ROE: -- 5.38 14.21

BRIEF-Transgene Says ‍First Patient Dosed In China In Trial Of T101​

* ‍FIRST CHRONIC HEPATITIS B PATIENT DOSED IN CHINA IN A PHASE 1 TRIAL OF T101​

17 Jan 2018

BRIEF-Transgene Announces ‍Dosing Of First Patient In Phase 2 Trial Of TG4010 Evaluation ​

* ‍FIRST PATIENT DOSED IN A PHASE 2 TRIAL WITH TRANSGENE'S TG4010 + NIVOLUMAB + CHEMOTHERAPY FOR FIRST-LINE TREATMENT OF LUNG CANCER (NSCLC)​

16 Jan 2018

BRIEF-Transgene Collaborates with BioInvent To Treat Solid Tumors

* BIOINVENT AND TRANSGENE COLLABORATE ON NEXT GENERATION ONCOLYTIC VIRUSES ENCODING AN ANTI-CTLA-4 ANTIBODY TO TREAT SOLID TUMORS

06 Dec 2017

BRIEF-Transgene successfully raises 14.4 million euros

* TRANSGENE SUCCESSFULLY RAISES € 14.4 MILLION FROM U.S. AND EUROPEAN INVESTORS

10 Nov 2017

BRIEF-Transgene launches capital increase by accelerated book-build offering

* TRANSGENE LAUNCHES A CAPITAL INCREASE BY WAY OF AN ACCELERATED BOOK-BUILD OFFERING

09 Nov 2017

BRIEF-Transgene announces first patient has been treated in TG6002 trial

* ‍FIRST PATIENT TREATED IN A PHASE 1/2A TRIAL (ONCOVIRAC) OF NOVEL ONCOLYTIC VIRUS TG6002 IN RECURRENT GLIOBLASTOMA​

26 Oct 2017

BRIEF-Transgene's TG1050 well tolerated and induces strong specific immune response

* TG1050 IS WELL TOLERATED AND INDUCES A STRONG SPECIFIC IMMUNE RESPONSE IN PATIENTS WITH CHRONIC HEPATITIS B Source text for Eikon: Further company coverage: (Gdynia Newsroom)

23 Oct 2017

BRIEF-Transgene Q3 operating revenue drops to 1.4‍​ million euros

* Q3 OPERATING REVENUE EUR 1.4‍​ MILLION VERSUS EUR 1.5 MILLION YEAR AGO

19 Oct 2017

BRIEF-Transgene presents clinical data on TG1050 regarding chronic hepatitis B​

* ‍TRANSGENE PRESENTS FIRST CLINICAL DATA INDICATING THAT TG1050 INDUCES A ROBUST AND HBV-SPECIFIC CELL-MEDIATED IMMUNE RESPONSE IN PATIENTS WITH CHRONIC HEPATITIS B​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

17 Oct 2017

BRIEF-Transgene peer reviewed TG4010’s ability to induce broad CD8+ responses

* PEER REVIEWED SCIENTIFIC PUBLICATIONS HIGHLIGHT TG4010’S ABILITY TO INDUCE BROAD CD8+ RESPONSES AND ITS SYNERGISTIC EFFECTS IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITORS Source text for Eikon: Further company coverage: (Gdynia Newsroom)

12 Oct 2017

Earnings vs. Estimates